What are the clinical signs of meropenem toxicity and its adverse effects?

Signs of Meropenem Toxicity and Adverse Effects

The most critical signs of meropenem toxicity are neurological manifestations—particularly seizures, delirium, confusion, and altered mental status—especially in patients with renal impairment, CNS disorders, or those receiving high doses. 11

Neurological Toxicity (Most Serious)

Neurotoxicity is the primary concern with meropenem and requires immediate recognition:

• Seizures: Incidence of drug-related seizures is 0.07-0.08% in non-meningitis infections 123
• Delirium and confusion: Common neuropsychiatric manifestations
• Agitation, hallucinations, and altered consciousness
• Paresthesias (tingling/numbness)
• Headache (reported in 2.3% of patients) 1
• Somnolence, anxiety, depression, and asthenia 11

Critical Risk Factors for Neurotoxicity:

• Renal impairment (most important—drug accumulation occurs rapidly) 11
• CNS disorders or history of seizures
• Concomitant use with valproic acid (causes breakthrough seizures) 1
• High doses without renal adjustment
• Elderly patients 4

Important caveat: In patients with moderately severe renal impairment (creatinine clearance 10-26 mL/min), the incidence of seizures, heart failure, kidney failure, and shock significantly increases 11. Dose adjustment is mandatory in renal dysfunction.

Gastrointestinal Effects

The most common adverse effects overall are gastrointestinal 11:

• Diarrhea (4.8% incidence—most common adverse effect)
• Nausea/vomiting (3.6%)
• Constipation (1.4%)
• Abdominal pain
• Clostridioides difficile-associated diarrhea (can occur with any broad-spectrum antibiotic) 1

These are generally mild but monitor for severe or persistent symptoms.

Hematologic Toxicity

• Thrombocytopenia: Observed particularly in patients with renal impairment, though clinical bleeding is rare 11
• Anemia (5.5% in some studies)
• Eosinophilia
• Leukocytosis
• Monitor: CBC with differential, platelet count 1

Hepatic Effects

• Elevated liver enzymes: ALT, AST, alkaline phosphatase, LDH (1.5-4.3% incidence) 13
• Cholestatic jaundice/jaundice
• Hepatic failure (rare)
• Monitor: Baseline and periodic liver function tests, especially if underlying liver disease

Renal Toxicity

• Increased creatinine and BUN 1
• Kidney failure (particularly in those with pre-existing renal impairment)
• Hypokalemia (5% in infants) 5
• Monitor: Serum creatinine, BUN, electrolytes

Local Injection Site Reactions

• Inflammation at injection site (2.4%)
• Phlebitis/thrombophlebitis (0.8%)
• Pain at injection site (0.4%)
• Edema at injection site (0.2%) 11

Hypersensitivity Reactions

• Rash (1.9% incidence) 1
• Pruritus (1.2%)
• Urticaria
• Severe cutaneous adverse reactions (rare but serious—Stevens-Johnson syndrome, toxic epidermal necrolysis) 1
• Anaphylaxis (rare)

Cardiovascular Effects

Less common but serious 11:

• Heart failure
• Cardiac arrest
• Hypotension/hypertension
• Tachycardia/bradycardia
• Myocardial infarction

Respiratory Effects

• Apnea (1.3%)
• Dyspnea
• Respiratory disorder
• Pulmonary edema 1

Monitoring Recommendations

For all patients on meropenem:

1. Baseline: CBC with differential, platelet count, creatinine, BUN, electrolytes, liver enzymes 1
2. During therapy:
   • Monitor neurological status closely—any unexplained confusion, agitation, or seizure activity warrants immediate evaluation and possible drug discontinuation 4
   • Renal function monitoring, especially in elderly and those with baseline impairment
   • Periodic CBC and liver function tests
3. High-risk patients (renal impairment, CNS disorders, elderly): More frequent monitoring and consider therapeutic drug monitoring (TDM) if available 46

Key Clinical Pitfalls

1. Failure to adjust dose in renal impairment: This is the most common cause of neurotoxicity 11
2. Missing early neurological signs: Subtle confusion or agitation may precede seizures
3. Continuing meropenem despite unexplained neurological symptoms: If neurotoxicity is suspected, temporarily suspend administration and investigate 4
4. Co-administration with valproic acid: This combination significantly increases seizure risk and should be avoided 1

The overall safety profile of meropenem is favorable, with most adverse events being mild and self-limited 23. However, vigilance for neurotoxicity—particularly in renally impaired patients—is essential for safe use.